View source for Company:Evogene

{{More citations needed
| date = December 2020}}
{{Infobox company
| name     = Evogene Ltd.
| logo     = Evogene logo New.jpg
| slogan   =
| type     = Public 
| traded_as        =  {{TASE|EVGN}} <br> {{NYSE|EVGN}}
| foundation       = 2002
| founder          = Dr. Hagai Karchi and Dr. Rafi Meissner
| location         = Rehovot, Israel
| origins          = 
| key_people       = Martin Gerstel, [[Social:Chairman|Chairman of Board]], Ofer Haviv, President & CEO
| area_served      = 
| industry         = Computational Biology
| subsid           = Biomica, Canonic, Lavie Bio, AgPlenus, Castera
| owner            =
| homepage         = {{URL|http://www.evogene.com}}
| footnotes        = 
}}

'''Evogene''' is a [[Biology:Computational biology|computational biology]] company based in Israel. Evogene Ltd. (NASDAQ:EVGN) has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence ("AI"), while adding a deep understanding of biology and advanced biological technologies. Evogene is using its proprietary CPB platform to computationally design and develop next-generation life-science products based upon three core components: microbes, small molecules, and genetic elements.

Evogene's computational platform allows it to substantially increase the probability of successful life-science product development, increase the efficacy and reduce the toxicity of its life-science products while reducing time and cost to development. Its strategic partners include BASF (OTCQX:BASFY), Bayer (OTCPK:BAYZF), Corteva (CTVA), ICL Group Ltd. (ICL) as well as various academic and medical institutions.


[[Category:Companies listed on the New York Stock Exchange]]



{{Cleanup_bare_URLs|date=2021}}
{{Sourceattribution|Evogene}}